Crystallis Therapeutics was formed when VC firm Novo Ventures, interested in the gout market, approached a management team with relevant experience. Together, they co-created the company to find and acquire a promising drug asset, reversing the typical founder-led model.

The CEO believes the most profound lessons in biotech come from speaking with founders of companies that did not succeed. In an industry defined by high clinical trial risk, understanding the missteps and navigating the challenges of unsuccessful ventures provides more practical wisdom than studying success stories alone.

Instead of relying on finding novel targets, a key strategy in neuropsychiatry is to revisit failed compounds that showed efficacy signals. Companies use modern chemistry and delivery to engineer solutions that separate efficacy from the historical liabilities that halted development, turning past failures into new opportunities.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

A decade ago, Neurocrine made the difficult decision to pause development of a promising CRF2 agonist. This ruthless prioritization freed up essential capital and focus to successfully develop what became INGREZZA, their blockbuster drug, demonstrating a long-term strategy of sacrificing a good opportunity for a great one.

Acadia's experimental drug, Remlefanserin, was designed specifically to address the limitations of its marketed drug, Newplazid. By eliminating a side effect (QT prolongation) that capped the dosage of the original drug, the new molecule can be tested at higher, potentially more effective, exposures, demonstrating a strategy of iterative, targeted improvement in drug development.

While the FDA's primary endpoint for gout drugs is a simple biomarker (uric acid levels), Crystallis designed its Phase 3 trials around harder clinical endpoints like flare reduction. This forward-thinking strategy aims to generate data needed to convince payers of the drug's value, ensuring market access post-approval.

Acadia's R&D process starts by considering what will ultimately matter to patients, physicians, and payers. This "end in mind" approach ensures clinical trials are designed to demonstrate meaningful, commercially relevant benefits. It forces realism about a drug's potential impact early in development, avoiding wasted resources on therapies that won't be adopted.

Xenon successfully de-risked the biologically validated but previously failed KV7 epilepsy target. They designed a new chemical structure that prevents dimerization, the molecular action responsible for the severe side effects that caused GSK's earlier drug to be withdrawn. This showcases a strategy of innovating on chemistry to solve known safety issues of a proven mechanism.